Literature DB >> 19047320

Insulin resistance in pulmonary arterial hypertension.

R T Zamanian1, G Hansmann, S Snook, D Lilienfeld, K M Rappaport, G M Reaven, M Rabinovitch, R L Doyle.   

Abstract

Although obesity, dyslipidemia and insulin resistance (IR) are well known risk factors for systemic cardiovascular disease, their impact on pulmonary arterial hypertension (PAH) is unknown. The present authors' previous studies indicate that IR may be a risk factor for PAH. The current study has investigated the prevalence of IR in PAH and explored its relationship with disease severity. Clinical data and fasting blood samples were evaluated in 81 nondiabetic PAH females. In total, 967 National Health and Nutrition Examination Surveys (NHANES) females served as controls. The fasting triglyceride to high-density lipoprotein cholesterol ratio was used as a surrogate of insulin sensitivity. While body mass index was similar in NHANES versus PAH females (28.6 versus 28.7 kg.m(-2)), PAH females were more likely to have IR (45.7 versus 21.5%) and less likely to be insulin sensitive (IS; 43.2 versus 57.8%). PAH females mostly (82.7%) had New York Heart Association (NYHA) class II and III symptoms. Aetiology, NYHA class, 6-min walk-distance and haemodynamics did not differ between IR and IS PAH groups. However, the presence of IR and a higher NYHA class was associated with poorer 6-months event-free survival (58 versus 79%). Insulin resistance appears to be more common in pulmonary arterial hypertension females than in the general population, and may be a novel risk factor or disease modifier that might impact on survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047320      PMCID: PMC2785883          DOI: 10.1183/09031936.00000508

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  48 in total

1.  Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

Authors:  Tzung-Dau Wang; Wen-Jone Chen; Jong-Wei Lin; Ming-Fong Chen; Yuan-Teh Lee
Journal:  Am J Cardiol       Date:  2004-02-01       Impact factor: 2.778

2.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

3.  Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.

Authors:  Markus C Stühlinger; Fahim Abbasi; James W Chu; Cindy Lamendola; Tracey L McLaughlin; John P Cooke; Gerald M Reaven; Philip S Tsao
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

4.  Long-term endothelin receptor blockade improves cardiovascular function in diabetes.

Authors:  S Verma; E Arikawa; J H McNeill
Journal:  Am J Hypertens       Date:  2001-07       Impact factor: 2.689

5.  Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats.

Authors:  Yasuhiro Ikeda; Yoshikazu Yonemitsu; Chu Kataoka; Shiro Kitamoto; Terutoshi Yamaoka; Ken-Ichi Nishida; Akira Takeshita; Kensuke Egashira; Katsuo Sueishi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

6.  Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.

Authors:  N Suskin; R S McKelvie; R J Burns; R Latini; D Pericak; J Probstfield; J L Rouleau; C Sigouin; C B Solymoss; R Tsuyuki; M White; S Yusuf
Journal:  Eur Heart J       Date:  2000-08       Impact factor: 29.983

7.  Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells.

Authors:  F Martin-Nizard; C Furman; P Delerive; A Kandoussi; J C Fruchart; B Staels; P Duriez
Journal:  J Cardiovasc Pharmacol       Date:  2002-12       Impact factor: 3.105

8.  Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Authors:  Steven M Haffner; Andrew S Greenberg; Wayde M Weston; Hongzi Chen; Ken Williams; Martin I Freed
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

9.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Authors:  Georg Hansmann; Vinicio A de Jesus Perez; Tero-Pekka Alastalo; Cristina M Alvira; Christophe Guignabert; Janine M Bekker; Stefan Schellong; Takashi Urashima; Lingli Wang; Nicholas W Morrell; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

10.  Use of metabolic markers to identify overweight individuals who are insulin resistant.

Authors:  Tracey McLaughlin; Fahim Abbasi; Karen Cheal; James Chu; Cindy Lamendola; Gerald Reaven
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  119 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  The role of mitochondria in pulmonary vascular remodeling.

Authors:  Peter Dromparis; Gopinath Sutendra; Evangelos D Michelakis
Journal:  J Mol Med (Berl)       Date:  2010-08-24       Impact factor: 4.599

Review 3.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

4.  Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

Authors:  Allan Lawrie; Abdul G Hameed; Janet Chamberlain; Nadine Arnold; Aneurin Kennerley; Kay Hopkinson; Josephine Pickworth; David G Kiely; David C Crossman; Sheila E Francis
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

Review 5.  Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training?

Authors:  Marios Panagiotou; Andrew J Peacock; Martin K Johnson
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

6.  O-linked β-N-acetylglucosamine transferase directs cell proliferation in idiopathic pulmonary arterial hypertension.

Authors:  Jarrod W Barnes; Liping Tian; Gustavo A Heresi; Carol F Farver; Kewal Asosingh; Suzy A A Comhair; Kulwant S Aulak; Raed A Dweik
Journal:  Circulation       Date:  2015-02-06       Impact factor: 29.690

7.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension.

Authors:  Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes
Journal:  J Heart Lung Transplant       Date:  2011-04-13       Impact factor: 10.247

Review 8.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

9.  Elevated pulmonary pressure: A novel risk marker in kidney disease?

Authors:  Sankar D Navaneethan; Raed A Dweik
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

10.  Echocardiographic findings and plasma endothelin-1 levels in obese patients with and without obstructive sleep apnea.

Authors:  Pierluigi Carratù; Valentina Anna Ventura; Mauro Maniscalco; Silvano Dragonieri; Simona Berardi; Roberto Ria; Vitaliano Nicola Quaranta; Angelo Vacca; Fiorella Devito; Marco Matteo Ciccone; Barbara Anne Phillips; Onofrio Resta
Journal:  Sleep Breath       Date:  2015-09-18       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.